Global CD22 Targeted Therapies Market, Approved Drug Sales, Technology Platforms & Clinical Trials Insight 2026

PUBLISHED: November 1, 2025

PAGES: 120 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

List of Tables

Global CD22 Targeted Therapies Market, Approved Drug Sales, Technology Platforms and Clinical Trials Insight 2026 Report Findings & Highlights:

Current & Future Global Market Outlook
Insight On CD22 Targeted Approaches
Approved Drug Dosage, Price & Sales Insight
CD22 Targeted Therapies Development Trends By Region & Indications
CD22 Targeted Therapies In Clinical Trials: > 20 Therapies
CD22 Targeted Therapies Clinical Trials Insight By Company, Country, Indication and Phase
CD22 Targeted Therapies Proprietary Technologies By Company

CD22 Targeted Therapies Need & Why This Report?

As the landscape of cancer therapies evolves, there is an increasing demand for treatments that specifically target the CD22 protein, which is found on the surface of B-cells and is overexpressed in several blood cancers, including acute lymphoblastic leukemia, large B-cell lymphoma and hairy cell leukemia. These therapies offer the potential for more precise, effective options, especially for patients with conditions in relapsed or refractory states who have exhausted conventional therapies. The report is designed to give stakeholders an overview of the current landscape regarding CD22 targeted therapies, offering an understanding of clinical trials, technological platforms, and key players driving innovation in the space.

Clinical Studies & Trials Insight Included In Report

This report provides comprehensive analysis for ongoing clinical studies and trials targeting CD22, covering a wide array of geographies, patient segments, and therapeutic approaches. Insights include data on monotherapies and combination therapies, highlighting the therapeutic potential of combining agents targeting CD22 with other treatments, such as CD19 or CD20 directed therapies. The report also covers trial sponsors, giving stakeholders a clear view on which companies, academia, and research institutes are advancing the development of treatments utilizing CD22. Additionally, it provides regional insights that allow for the identification of emerging markets and regions where the adoption of CD22 targeted therapies is gaining momentum or facing regulatory challenges.

Technology Platforms Included In Report

One of the key highlights of the report is the in-depth analysis of innovative technology platforms that are dramatically changing how CD22 targeted therapies are developed. For example, TALEN(R) (Transcription Activator-Like Effector Nucleases) by Cellectis is a gene-editing platform that enables precise genome editing and proves especially instrumental in cell therapy development, including Lasme-cel (UCART22) and Eti-cel (UCART20x22). TALEN(R) technology enables highly accurate gene modifications, such as knockouts, insertions, and deletions, allowing for the manufacturing of more effective and targeted treatments. The report provides an in-depth review of such platforms and their application in the CD22 space, giving insight into how these technologies are redefining the future of cell-based immunotherapies.

Leading Companies Engaged In R&D Of CD22 Targeted Therapies

The report also profiles the leading companies driving research and development in CD22 targeted therapies, including major biotech and pharmaceutical companies such as Pfizer, AstraZeneca, and Umoja Biopharma, among others. Emerging players specialize in cell-based therapies and innovative delivery systems. This report analyzes the strategies being pursued, progress made, and the potential for these companies to bring CD22 targeted therapies to the forefront of cancer treatment. Gaining insight into a company's research pipeline and development priorities enables stakeholders to more accurately assess the direction of this exciting therapeutic area.

Report Indicating Future Direction Of CD22 Targeted Therapies

This report provides the future direction of these therapies as the landscape of CD22 targeted therapies continuously evolves. The next waves of innovation, from advances in CAR-T cell therapies to the integration of nanobody based technologies, are identified in this report. As explained, new combinations and multi target approaches have the potential to overcome major challenges such as antigen escape and relapse and, therefore, will drive improved efficacy and patient outcomes. This report is an important tool for stakeholders seeking to understand where CD22 targeted therapies are headed and how to position themselves for success in this rapidly developing field.

1. Research Methodology

2. Introduction To CD22

2.1 Overview Of CD22 Targeted Therapies
2.2 Importance Of CD22 In Immunology

3. Biology Of CD22

3.1 Structure & Function of CD22
3.2 Role In B-cell Development & Function
3.3 Mechanisms Of Action In Immune Response

4. CD22 Targeted Approaches

4.1 Cell Therapies
4.2 Antibody Therapies
4.3 Radioimmunoconjugates
4.4 Nucleic Acids

5. Global CD22 Targeted Therapies Market Outlook

5.1 Current Market Scenario
5.2 Future Market Opportunities

6. Besponsa - Dosage, Price & Sales Insight

6.1 Overview & Availability Insight
6.2 Pricing & Dosage Insight
6.3 Sales Insight

7. CD22 Targeted Therapies Regional Market Analysis

7.1 US
7.2 Europe

8. CD22 Targeted Therapies Development & Clinical Trends By Indication

8.1 Cancer
8.2 Neurodegenerative Diseases
8.3 Autoimmune & Inflammatory Diseases
8.4 Infectious Diseases

9. Global CD22 Targeted Therapy Clinical Trials Overview

9.1 By Country
9.2 By Indication
9.3 By Organization
9.4 By Phase

10. Global CD22 Targeted Therapy Clinical Trials Insight By Company, Country, Indication & Phase

10.1 Research
10.2 Preclinical
10.3 Phase I
10.4 Phase I/II
10.5 Preregistration

11. Marketed CD22 Targeted Therapies Clinical Insight By Company, Country, Indication & Phase

12. Global CD22 Targeted Therapies Market Dynamics

12.1 Drivers & Opportunities
12.2 Challenges & Solutions

13. CD22 Targeted Therapies Development Platforms By Company

14. Competitive Landscape

14.1 ADC Therapeutics
14.2 AstraZeneca
14.3 Autolus Therapeutics
14.4 Cellectis
14.5 Century Therapeutics
14.6 Enterome
14.7 Essen BioTech
14.8 Kecellitics Biotech
14.9 ME Therapeutics
14.10 Miltenyi Biomedicine
14.11 Nanjing IASO Biotechnology
14.12 NanoCell Therapeutics
14.13 Onechain Immunotherapeutics
14.14 Pfizer
14.15 Regeneron
14.16 Shanghai Yake Biotechnology
14.17 SinoMab Bioscience
14.18 TuHURA Biosciences
14.19 Umoja Biopharma

List of Figures

Figure 2-1: CD22 As A Therapeutic Target
Figure 2-2: Evolution Of CD22 Targeted Therapy
Figure 2-3: CD22 In Immune Regulation
Figure 2-4: CD22 In The B-Cell Signaling Network
Figure 2-5: How CD22 Dampens BCR Signaling
Figure 3-1: Domain Architecture Of CD22
Figure 3-2: CD22 Mediated Inhibition Of BCR Signaling
Figure 3-3: Dual Signaling Roles Of CD22
Figure 3-4: CD22 Oligomerization & B-Cell Activation Threshold
Figure 3-5: CD22 Adhesion & Immune Synapse Positioning
Figure 3-6: CD22 In Calcium Regulation
Figure 3-7: CD22's Multi-Layered Control Of Immune Responses
Figure 4-1: CD22 Targeted CAR-T Cell Therapy - Mechanism
Figure 4-2: Targeting CD22 After CD19 Antigen Escape
Figure 4-3: Multi-Antigen CAR Concept Featuring CD22
Figure 4-4: CD22 Targeted Antibody Based Therapies
Figure 4-5: Besponsa - Mechanism Of Action
Figure 4-6: Lumoxiti - Mechanism Of Action
Figure 4-7: CD22-Targeted Radioimmunoconjugates - Mechanism Of Action
Figure 4-8: CD22 Radioimmunoconjugates - Advantages
Figure 4-9: CD22 Nucleic Acid Targeting Approaches
Figure 4-10: Targeting CD22 With RNA-Based Therapeutics
Figure 5-1: CLIC-02 Phase 1 (NCT06208735) Study - Initiation & Completion Year
Figure 5-2: Global CD22 Targeted Therapies Market - Future Opportunities
Figure 6-1: Besponsa - Approval Year By Region
Figure 6-2: Besponsa - Cost Of Supply By Region, November'2025
Figure 6-3: Besponsa - Global Annual Sales (US$ Million), 2020-2023
Figure 6-4: Besponsa - Global Sales by Region (US$ Million), 2023
Figure 6-5: Besponsa - Global Quarterly Sales (US$ Million), Q1-Q4'2023
Figure 8-1: SIDNEY Phase 1/2 (NCT04669171) Study - Initiation & Completion Year
Figure 8-2: BZE2204-A-01 Phase 1 (NCT06446128) Study - Initiation & Completion Year
Figure 8-3: BZE2204-C-01 Phase 1 (NCT07174843) Study - Initiation & Completion Year
Figure 9-1: Global - Number Of CD22 Targeted Therapy Clinical Trials By Country, 2026
Figure 9-2: Global - Number Of CD22 Targeted Therapy Clinical Trials By Indication, 2026
Figure 9-3: Global - Number Of CD22 Targeted Therapy Clinical Trials By Organization, 2026
Figure 9-4: Global - Number Of CD22 Targeted Therapy Clinical Trials By Phase, 2026
Figure 12-1: Global CD22 Targeted Therapies Market - Drivers & Opportunities
Figure 12-2: Global CD22 Targeted Therapies Market - Challenges & Solutions
Figure 13-1: TRAAC - Tallac Therapeutics
Figure 13-2: VivoVec Platform - Unique Features
Figure 13-3: OncoMimics Platoform
Figure 13-4: Cellectis - TALEN Technology